MANETTI, NATALIA
 Distribuzione geografica
Continente #
NA - Nord America 154
EU - Europa 122
AS - Asia 41
AF - Africa 1
OC - Oceania 1
Totale 319
Nazione #
US - Stati Uniti d'America 154
RU - Federazione Russa 47
IT - Italia 24
PL - Polonia 18
IE - Irlanda 15
SG - Singapore 13
SE - Svezia 12
CN - Cina 11
HK - Hong Kong 7
VN - Vietnam 5
FR - Francia 2
IN - India 2
JO - Giordania 2
UA - Ucraina 2
CI - Costa d'Avorio 1
DE - Germania 1
GB - Regno Unito 1
KR - Corea 1
NZ - Nuova Zelanda 1
Totale 319
Città #
Santa Clara 40
Warsaw 18
Dublin 15
Fairfield 15
Singapore 12
Chandler 10
Ashburn 7
Altamura 6
Kent 6
Woodbridge 6
Lawrence 5
Rapolano Terme 5
Florence 4
Hong Kong 4
Moscow 4
Seattle 4
Wilmington 4
Ann Arbor 3
Boston 3
Buffalo 3
Cambridge 3
Houston 3
Princeton 3
Shanghai 3
Beijing 2
Cagliari 2
Dong Ket 2
Mumbai 2
New York 2
Paris 2
Abidjan 1
Boardman 1
Graysville 1
Guangzhou 1
Hamilton 1
Hillsboro 1
Incisa 1
Jacksonville 1
London 1
Medford 1
Milan 1
Montesilvano 1
Norwalk 1
Redmond 1
Redwood City 1
San Gavino Monreale 1
Seoul 1
Shenyang 1
Shenzhen 1
Totale 217
Nome #
The Clinical Value of Fluorescent Lymphography with Indocyanine Green During Robotic Surgery for Gastric Cancer: a Matched Cohort Study 128
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. 70
PROSIT Investigators. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy 66
Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study 61
Totale 325
Categoria #
all - tutte 1.180
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.180


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202020 0 0 0 0 0 2 6 4 4 2 2 0
2020/202144 1 2 0 0 2 1 3 8 4 16 2 5
2021/202225 0 2 4 0 2 0 4 0 0 1 4 8
2022/202371 4 14 3 2 3 14 12 5 8 1 5 0
2023/202440 0 3 4 1 4 5 5 8 0 1 9 0
2024/2025115 9 18 15 23 50 0 0 0 0 0 0 0
Totale 325